Abstract
PREVIEWTreatment of venous thromboembolism is undergoing rapid change, particularly with the advent of low- molecular-weight heparins. But how does the performance of these new agents stack up against standard treatment with unfractionated heparin? And what are the issues involved in thrombolytic therapy for deep venous thrombosis and pulmonary embolism? Drs Yacovella and Alter make sense of the current data and controversies regarding anticoagulation and thrombolytic therapy. They also discuss consensus opinion about the available therapeutic options and, when consensus is lacking, offer their own recommendations on appropriate choices and duration of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
